MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Regeneron Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

625.29 1.37

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

610.05

Максимум

627.04

Ключови измерители

By Trading Economics

Приходи

-423M

918M

Продажби

69M

3.8B

P/E

Средно за сектора

16.529

63.778

EPS

12.07

Дивидентна доходност

0.56

Марж на печалбата

24.219

Служители

15,106

EBITDA

-534M

1.1B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+51.62% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

0.56%

2.39%

Следващи печалби

29.04.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-5B

70B

Предишно отваряне

623.92

Предишно затваряне

625.29

Настроения в новините

By Acuity

52%

48%

321 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

Regeneron Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.02.2025 г., 12:13 ч. UTC

Печалби

Regeneron 4Q Revenue Up on Strong Sales of EYLEA HD

8.07.2024 г., 12:00 ч. UTC

Печалби

Regeneron Expects Earnings Hit After $24 Million R&D Charge

28.02.2025 г., 12:00 ч. UTC

Топ новини

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4.02.2025 г., 11:58 ч. UTC

Печалби

Regeneron 4Q Rev Up on Strong Sales of EYLEA HD

4.02.2025 г., 11:37 ч. UTC

Печалби

Regeneron Pharma Sees 2025 Adjusted R&D $5B-$5.2B >REGN

4.02.2025 г., 11:37 ч. UTC

Печалби

Regeneron Pharma Sees 2025 Gross Margin on Net Product Sales 87%-88% >REGN

4.02.2025 г., 11:36 ч. UTC

Печалби

Regeneron Pharma Sees 2025 Capital Spending $850M-$975M >REGN

4.02.2025 г., 11:35 ч. UTC

Печалби

Regeneron Pharma Declares Initial Quarterly Dividend of 88c >REGN

4.02.2025 г., 11:35 ч. UTC

Печалби

Regeneron Pharma 4Q Adj EPS $12.07 >REGN

4.02.2025 г., 11:34 ч. UTC

Печалби

Regeneron Pharma 4Q U.S. Net Sales for Eylea HD, Eylea Rose 2% to $1.5B >REGN

4.02.2025 г., 11:34 ч. UTC

Печалби

Regeneron Pharma: 4Q Dupixent Global Net Sales Recorded by Sanofi Rose 15% to $3.7B >REGN

4.02.2025 г., 11:32 ч. UTC

Печалби

Regeneron Pharma Board OKs Additional $3 Billion Share Repurchase >REGN

4.02.2025 г., 11:31 ч. UTC

Печалби

Regeneron Pharma Initiates Quarterly Cash Dividend Program >REGN

31.01.2025 г., 08:30 ч. UTC

Придобивния, сливания и поглъщания

It's Bananas, but Stock Splits Can Pay Off. Here Are 5 Likely Contenders. -- Barrons.com

28.01.2025 г., 10:30 ч. UTC

Топ новини

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

31.10.2024 г., 13:58 ч. UTC

Печалби

Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom -- IBD

31.10.2024 г., 10:52 ч. UTC

Печалби

Regeneron Earnings Top Views For Biotech Giant -- IBD

31.10.2024 г., 10:34 ч. UTC

Печалби

Regeneron Pharma 3Q Adj EPS $12.46 >REGN

31.10.2024 г., 10:33 ч. UTC

Печалби

Regeneron Pharma 3Q EPS Cut 43c by Acquired IPR&D Charge >REGN

31.10.2024 г., 10:33 ч. UTC

Печалби

Regeneron Pharma 3Q U.S. Sales for Eylea HD, Eylea Rose 3% to $1.54B >REGN

31.10.2024 г., 10:32 ч. UTC

Печалби

Regeneron Pharma: 3Q Dupixent Global Net Sales Recorded by Sanofi Rose 23% to $3.82B >REGN

31.10.2024 г., 10:30 ч. UTC

Печалби

Regeneron Pharma 3Q Rev $3.72B >REGN

31.10.2024 г., 10:30 ч. UTC

Печалби

Regeneron Pharma 3Q EPS $11.54 >REGN

31.10.2024 г., 10:30 ч. UTC

Печалби

Regeneron Pharma 3Q Net $1.34B >REGN

25.10.2024 г., 20:25 ч. UTC

Печалби

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

1.08.2024 г., 11:50 ч. UTC

Печалби

Regeneron Stock Climbs After Strong Second-Quarter Performance -- IBD

1.08.2024 г., 10:37 ч. UTC

Печалби

Regeneron Pharma 2Q Adj EPS $11.56 >REGN

1.08.2024 г., 10:30 ч. UTC

Печалби

Regeneron Pharma 2Q EPS $12.41 >REGN

1.08.2024 г., 10:30 ч. UTC

Печалби

Regeneron Pharma 2Q Net $1.43B >REGN

1.08.2024 г., 10:30 ч. UTC

Печалби

Regeneron Pharma 2Q Rev $3.55B >REGN

Сравнение с други в отрасъла

Ценова промяна

Regeneron Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

51.62% нагоре

12-месечна прогноза

Среден 948.55 USD  51.62%

Висок 1,182 USD

Нисък 575 USD

Според 20 анализатори от Wall Street, предложили 12-месечна ценова цел за Regeneron Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

20 ratings

16

Купи

3

Задържане

1

Продай

Техническа оценка

By Trading Central

N/A / 662.33Подкрепа & съпротива

Краткосрочен план

Bearish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

321 / 386 Класиране в Здравеопазване

Настроения в новините

Мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.